15.18% reported weight loss · placebo result not extracted · 36 weeks
48 mg every two weeks
US adults with overweight or obesity without type 2 diabetes
Per-protocol population; not treatment-policy. Phase 3 positive; registration/commercialization partnerships advancing.
Safety context
Most reported adverse events were mild or moderate gastrointestinal events.
Limitations: Latest verified no-T2D cohort. Sponsor topline per-protocol analysis, with placebo percentage undisclosed. Active tirzepatide comparator was open-label; bofanglutide and placebo were double-blind.
No approved trade name verified. GZR18 is a development code; licensing in Europe, India, Korea or Latin America is not an approval in those regions.
Gan & Lee Pharmaceuticals · Originator and global clinical developer.; Menarini Group · Exclusive European registration and commercialization partner.; JW Pharmaceutical · Exclusive South-Korean development and commercialization licensee.; Lupin · Exclusive Indian development and commercialization licensee.; Productos Científicos / CARNOT Laboratorios · Latin-American development and commercialization licensee, including Mexico and Brazil.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
The molecule
A long-acting peptide that activates GLP-1 receptors.
Structure not yet verified
Structure not verified
A long-acting peptide that activates GLP-1 receptors.
Shown: Peptide drug
An exact-drug structure was not verified in this review. The named PubChem lookup did not return a compound record; no related hormone or analogue is substituted.